LOXL3 and neoplasm: Moreover, combination therapy using low-dose oxaliplatin and leflunomide (a DHODH inhibitor) effectively suppressed HCC progression and extended survival in both S704D-LOXL3 knock-in mice and transplanted tumor models with S704A-LOXL3 (Fig. 7) (Zhan et al., 2023).